Egis intensifies its acquisition strategy in 2017

Egis Pharmaceuticals PLC has acquired Sorbifer’s product rights from AstraZeneca. The transaction reinforces Egis’ position on its key markets. details >

Egis is one of the most attractive workplaces in the pharma industry

Our company was awarded based on the evaluation of employees and job seekers. details >

Dr. Klára András will be HR Director of Egis Pharmaceuticals PLC

from April 1, 2017 details >

Egis strengthens presence in Russia by OTC acquisition

Egis acquired Russian D-Panthenol and women’s health product portfolio from Jadran-Galenski Laboratorij’s (JGL). details >

Egis is investor of the month

The recognition, founded by the Minister of National Economy, is given the investors, SME-s and start-ups which have achieved outstanding results. In December 2016, Egis Pharmaceuticals was awarded “Investor of the month”. details >

Egis reports revenue from collaboration with Actavis

Egis Pharmaceuticals today announced that it has generated $110 million (USD) in revenue related to the collaboration and sale of generic rosuvastatin calcium by Actavis in the United States. details >